And excellent #MMsm editorial by Joshua Richter, MD, FACP! When we need a bridge over troubled water (well played), use alkylators but don’t overuse them. Plus an intriguing nod to GPRC5D bsAbs as bridging before BCMA CAR-T… Science at work! nature.com/articles/s4140…

ODAC unanimously votes in favor of using #MRD as an early endpoint for accelerated approval in #myeloma trials This was a huge team effort for more than 8 years and with the generosity of unprecedented data sharing from many investigators around the world. Thank you all! #mmsm

Real world data on bridging therapy for CAR-T. Report by U.S. Myeloma Immunotherapy Consortium Aimaz Afrough Yi Lin Surbhi Sidana, MD Gurbakhash Kaur Larry Anderson,MD,PhD,FACP Shonali Midha, M.D. Hamza Hashmi Krina Patel @MyelomaSLC Omar Nadeem et al. nature.com/articles/s4140…

See also accompanying editorial on Bridging Therapy for CAR-T in myeloma. Joshua Richter, MD, FACP The Tisch Cancer Institute #OpenAccess nature.com/articles/s4140…

Nobel laureate Dr. William Kaelin delivers the Seldin Symposium keynote address to a packed house! ⁦UT Southwestern Medical Center⁩ ⁦Thomas Wang, MD⁩ ⁦UTSW Internal Medicine Chiefs⁩ #SeldinSymposium2024

Natalie S. Callander, MD, on Multiple Myeloma: Management Updates ascopost.com/videos/2024-nc… #mmsm #MultipleMyeloma Natalie Callander UW Health | Carbone Cancer Center #hematology #guidelines #NCCN2024 National Comprehensive Cancer Network (NCCN)

Nobel laureate KaelinLab gave a special UT Southwestern Internal Medicine grand rounds this AM during the #SeldinSymposium — his journey from Duke University School of Medicine to Johns Hopkins Medicine & Harvard Medical School Dana-Farber & discoveries for anemia, ischemia, & #kidneycancer along the way. UTSW Simmons Cancer Center

Absolutely mind-blowing talk today by the brilliant John F. DiPersio Lab, visiting UTSW Simmons Cancer Center! On CART-cell therapy for #T-ALL, epitome of #BenchToBedside innovation! “EVERYONE is an expert and everyone has unproven approaches that become almost Mythical over time”. 😂🎉UTSW Hematology & Oncology

#ASCO24 DREAMM-7 Bela-Vd vs. Dara-Vd for RRMM. >/=2nd line. N=494, median F/U: 28.2 months. Median PFS 36.6 vs. 13.4 months favoring Bela-Vd (HR=0.41). More ocular AEs with Bela-Vd, improved with dose modifications #mmsm VaniaHungria marivi mateos NEJM nejm.org/doi/full/10.10…

Congrats to Dr. Saurabh Zanwar, Dr. Doris Hansen and the US Myeloma Immunotherapy Consortium for another great paper! Largest cohort evaluated to date for outcomes on EMD and PMD, both high risk factors for RRMM #mmsm Mayo Clinic Moffitt Cancer Center link.springer.com/10.1186/s13045…

Out now in Journal of Hematology and Oncology: Impact of Extramedullary Multiple Myeloma on Outcomes with Ide-cel: jhoonline.biomedcentral.com/articles/10.11… Shaji Kumar Yi Lin Krina Patel Surbhi Sidana, MD #dorishansen Moffitt Cancer Center BMC Top line results and a brief 🧵 1/

Happening now, poster P939 #EHA24. Love to hear your feedback. #CIBMTR

Instagram Post 📢 Big News! We are thrilled to announce that Suzanne Cole, MD, FACP, FASCO has been selected as one of the recipients of the 2023-2024 IM UME Outstanding Faculty Teaching Award! 🏆✨ UTSW Internal Medicine UTSW Simmons Cancer Center

Looking forward to this discussion with these outstanding colleagues #SOHO2024 #bmtsm #MDS #leusm

CONGRESS | #IMS2024 | PRESENTATION Meletios Dimopoulos Thanos Dimopoulos shares findings from a cytogenetic risk analysis of the phase III PERSEUS trial (N = 709), which demonstrated a significant PFS benefit for the addition of daratumumab (D) to VRd induction and consolidation

#IMS24 the US #MMsm immunotherapy consortium is growing and I could not be happier to see it! Surbhi Sidana, MD Krina Patel Binod Dhakal Plasma Cell Pete Larry Anderson,MD,PhD,FACP Noa Biran Jack Khouri Aimaz Afrough - missing Al Garfall Gurbakhash Kaur and many more!

Why? Excellent #IMS24 plenary by Machlachlan Memorial Sloan Kettering Cancer Center 👇 PMD and EMD look very different at a genomic level, and we should stop conflating them. Kudos to many junior faculty Saurabh Zanwar Danai Dima Aimaz Afrough Darren Pan et al who’ve helped show this clinically!

#Myeloma Paper of the Day: Whole genome sequencing of extramedullary disease in myeloma finds BRAF, NRAS, KRAS & MYC frequently implicated oncogenes, w/ frequent loss of tumor suppressor genes SP140 & TENT5C, suggesting central role of MAPK pathway: pubmed.ncbi.nlm.nih.gov/39799110/. #mmsm

#Myeloma Paper of the Day: Comparison of standard-of-care Ide-cel and Cilta-cel in relapsed/refractory myeloma finds Cilta associated w/ higher likelihood of grade ≥3 CRS, SPMs, and delayed neurotox, but better treatment responses, PFS, and OS: pubmed.ncbi.nlm.nih.gov/39965175/. #mmsm

Study now open UT Southwestern Medical Center. Patients newly diagnosed with MM in the Dallas area can receive personalized response-adapted treatment with the wonderful Larry Anderson,MD,PhD,FACP Aimaz Afrough HealthTree Foundation #MMSM UTSW Simmons Cancer Center